

## DAFTAR PUSTAKA

1. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. *Int J Antimicrob Agents*. 2020;55(5):1–13.
2. Wang R, Pan M, Zhang X, Han M, Fan X. Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang , Anhui , China. *Int J Infect Dis*. 2020;95:421–8.
3. Satuan Tugas Penanganan COVID-19. ANALISIS DATA COVID-19 INDONESIA UPDATE PER 28 FEBRUARI 2021. 2021; Tersedia pada: <https://covid19.go.id/p/berita/analisis-data-covid-19-indonesia-update-28-februari-2021>
4. DISKOMINFO Provinsi Sumbar. Data Pantauan COVID-19 Provinsi Sumatera Barat [Internet]. 2021. Tersedia pada: <https://corona.sumbarprov.go.id/>
5. Pemerintah Kota Padang. KONDISI COVID-19 KOTA PADANG [Internet]. 2021. Tersedia pada: <http://corona.padang.go.id/>
6. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. *J Chinese Med Assoc*. 2020;83(3):217–20.
7. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. *J Infect Public Health*. 2020;13:1833–9.
8. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. *JAMA - J Am Med Assoc*. 2020;323(20):2052–9.
9. Eman M, Daef E, Mohamed-hussein A, Mostafa EF, Hassany SM, Galal H, et al. Impact of comorbidities on COVID-19 outcome. Preprint. 2020;1–26.
10. Thiruvengadam G, Lakshmi M, Ramanujam R. A Study of Factors Affecting the Length of Hospital Stay of COVID-19 Patients by Cox-Proportional Hazard Model in a South Indian Tertiary Care Hospital. *J Prim Care Community Health*. 2021;12:1–7.
11. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J*. 2020;1–56.
12. World Health Organization. COVID-19 Clinical management : Living guidance. World Heal Organ [Internet]. 2021;1–101. Tersedia pada: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>
13. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. *Int J Infect Dis*. 2020;94:91–5.

14. Rauf A, Abu-izneid T, Olatunde A, Khalil AA, Alhumaydhi FA, Tufail T, et al. COVID-19 Pandemic : Epidemiology , Etiology , Conventional and Non-Conventional Therapies. *Int J Environ Res Public Health*. 2020;17(8155):1–32.
15. World Health Organization. COVID-19 Weekly Epidemiological Update 22. World Heal Organ [Internet]. 2021;1–33. Tersedia pada: [https://www.who.int/docs/default-source/coronaviruse/situation-reports/weekly\\_epidemiological\\_update\\_22.pdf](https://www.who.int/docs/default-source/coronaviruse/situation-reports/weekly_epidemiological_update_22.pdf)
16. Instalasi Rekam Medis RSUP Dr M Djamil Padang. Data Rekam Medis RSUP Dr. M Djamil Padang. 2021.
17. Ouassou H, Kharchoufa L, Bouhrim M. The Pathogenesis of Coronavirus Disease 2019 ( COVID-19 ): Evaluation and Prevention. *Hindawi J Immunol Res*. 2020;1–7.
18. Das SK. The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). *Indian J Clin Biochem*. 2020;35(4):385–96.
19. Parasher A. COVID-19 : Current understanding of its pathophysiology , clinical presentation and treatment. *Postgr Med J*. 2020;0:1–9.
20. Hafeez A, Ahmad S, Siddqui SA, Ahmad M. A Review of COVID-19 (Coronavirus Disease-2019) Diagnosis, Treatments and Prevention. *EJMO*. 2020;4(2):116–25.
21. Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020;324(8):782–93.
22. Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese N, et al. Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review. *Int J Environ Res Public Health*. 2020;17(2690):1–11.
23. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. *Clin Immunol*. 2020;215:1–8.
24. Lee C, Choi WJ. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. *Arch Pharm Res [Internet]*. 2021;44(1):99–116. Tersedia pada: <https://doi.org/10.1007/s12272-020-01301-7>
25. Rothan HA, Byraredy SN. The epidemiology and pathogenesis of coronavirus disease ( COVID-19 ) outbreak. *J Autoimmun*. 2020;1–9.
26. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo W, Susilo A, et al. Pedoman Tatalaksana COVID-19 edisi 3. PDPI, PERKI, PAPDI, PERDATIN, IDAI; 2020.
27. Grasselli G, Tonetti T, Protti A, Langer T, Girardis M, Bellani G, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome : a multicentre prospective observational study. *Lancet Respir Med*. 2020;8:1201–8.
28. Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus ( COVID-19 ): A Review of Clinical Features , Diagnosis , and Treatment. *Cureus*. 2020;12(3):1–5.
29. Azer SA. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. *New Microbes New Infect*. 2020;37(C):1–8.
30. Aziz H, Fatima S, Iqbal H, Faheem M. Recent Advances in Molecular diagnosis

- curbing the COVID-19. *Int J Infect Dis.* 2020;97:322–5.
31. Pascarella G, Strumia A, Piliengo C, Bruno F, Buono R Del, Agr FE, et al. COVID-19 diagnosis and management: a comprehensive review. *Assoc Publ J Intern Med.* 2020;288:192–206.
  32. NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. NIH [Internet]. 2021;1–274. Tersedia pada: <https://www.covid19treatmentguidelines.nih.gov/>
  33. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;1–10.
  34. Kim DW, Byeon KH, Kim J, Cho KD, Lee N. The correlation of comorbidities on the mortality in patients with COVID-19: An observational study based on the Korean national health insurance big data. *J Korean Med Sci.* 2020;35(26):1–9.
  35. Callender LA, Curran M, Bates SM, Mairesse M, Weigandt J, Betts CJ. The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. *Front Immunol.* 2020;11(1991):1–16.
  36. Bansal M. Cardiovascular disease and COVID-19. *Diabetes Metab Syndr Clin Res Rev.* 2020;14:247–50.
  37. Surendra H, Rf I, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta , Indonesia : A hospital-based retrospective cohort study. *Lancet Reg Heal.* 2021;9:0–8.
  38. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. *Nat Rev Cardiol* [Internet]. 2020;17:543–58. Tersedia pada: <http://dx.doi.org/10.1038/s41569-020-0413-9>
  39. Kamyshnyi A, Krynytska I, Matskevych V, Marushchak M, Lushchak O. Arterial hypertension as a risk comorbidity associated with covid-19 pathology. *Int J Hypertens.* 2020;1–7.
  40. Pan W, Zhang J, Wang M, Ye J, Xu Y, Shen B, et al. Clinical Features of COVID-19 in Patients with Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients. *Hypertension.* 2020;732–41.
  41. Bordallo B, Bellas M, Cortez AF, Vieira M, Pinheiro M. Severe COVID-19: What have we learned with the immunopathogenesis? *Adv Rheumatol.* 2020;60(50):1–13.
  42. Ugwueze C V., Ezeokpo BC, Nnolim BI, Agim EA, Anikpo NC, Onyekachi KE. COVID-19 and Diabetes Mellitus: The Link and Clinical Implications. *Dubai Diabetes Endocrinol J.* 2020;26:69–77.
  43. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *Am J Physiol - Endocrinol Metab.* 2020;318:E736–41.
  44. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. *SN Compr Clin Med.* 2020;1–9.
  45. Polverino F, Kheradmand F. COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects. *Front Med.* 2021;7:1–8.

46. Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. *Eur Respir J* [Internet]. 2020;56:1–9. Tersedia pada: <http://dx.doi.org/10.1183/13993003.02108-2020>
47. Olloquequi J. COVID-19 Susceptibility in chronic obstructive pulmonary disease. *Eur J Clin Invest*. 2020;50:1–8.
48. Gao Y dong, Ding M, Dong X, Zhang J jin, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy Eur J Allergy Clin Immunol*. 2021;76:428–55.
49. Sin DD. COVID-19 in COPD: A growing concern. *EclinicalMedicine*. 2020;26:1–2.
50. Lee SC, Son KJ, Han CH, Jung JY, Park SC. Impact of comorbid asthma on severity of coronavirus disease (COVID-19). *Sci Rep* [Internet]. 2020;10(21805):1–9. Tersedia pada: <https://doi.org/10.1038/s41598-020-77791-8>
51. Hughes-Visentin A, Paul ABM. Asthma and COVID-19: What do we know now. *Clin Med Insights Circ Respir Pulm Med*. 2020;14:1–7.
52. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. *Clin Rev Allergy Immunol*. 2020;59:78–88.
53. Irfani TH, Siburian R, Nabila R, Umar TP. Tuberculosis and coronavirus disease 2019 (COVID-19) from a clinical perspective: A systematic review. *Medeni Med J*. 2020;35(4):338–43.
54. Yang H, Lu S. COVID-19 and tuberculosis. *J Transl Intern Med*. 2020;8(2):59–65.
55. Visca D, Ong CWM, Tiberi S, Centis R, D'Ambrosio L, Chen B, et al. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. *Pulmonology*. 2021;27:151–65.
56. Bruchfeld A. The COVID-19 pandemic: consequences for nephrology. *Nat Rev Nephrol*. 2021;17(2):81–2.
57. Siepmann T, Sedghi A, Barlinn J, de With K, Mirow L, Wolz M, et al. Association of history of cerebrovascular disease with severity of COVID-19. *J Neurol* [Internet]. 2020;268(3):773–84. Tersedia pada: <https://doi.org/10.1007/s00415-020-10121-0>
58. Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19—systematic review, meta-analysis, and meta-regression. *J Stroke Cerebrovasc Dis*. 2020;29(8):1–9.
59. Lou M, Yuan D, Liao S, Tong L, Li J. Potential mechanisms of cerebrovascular diseases in COVID-19 patients. *J Neurovirol* [Internet]. 2021;27:35–51. Tersedia pada: <https://doi.org/10.1007/s13365-021-00948-2>
60. Ahmad A, Ishtiaq S, Khan J, Aslam R, Ali S, Arshad M. COVID-19 and comorbidities of hepatic diseases in a global perspective. *World J Gastroenterol*. 2021;27(13):1296–310.
61. Shields AM, Burns SO, Savic S, Al SET. COVID-19 in patients with primary and

secondary immunodeficiency : The United Kingdom experience. *J Allergy Clin Immunol.* 2021;870–6.

62. Rossouw TM, Boswell MT, Nienaber AG, Moodley K. Comorbidity in context: Part 1. Medical considerations around HIV and tuberculosis during the COVID-19 pandemic in South Africa. *South African Med J.* 2020;110(7):621–4.
63. Saleemi MA, Ahmad B, Benchoula K, Sufyan M. Emergence and molecular mechanism of SARS-CoV-2 and HIV to target host cells and potential therapeutics. *Infect Genet Evol.* 2020;85:1–15.
64. Sanchis-Gomar F, Lavie CJ, Mehra MR, Henry BM, Lippi G. Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide. *Mayo Clin Proc.* 2020;95(7):1445–53.
65. Bakouny Z, Hawley JE, Choueiri TK, Peters S, Rini BI, Warner JL, et al. COVID-19 and Cancer: Current Challenges and Perspectives. *Cancer Cell* [Internet]. 2020;38(5):629–46. Tersedia pada: <https://doi.org/10.1016/j.ccell.2020.09.018>
66. Feldman EL, Savelieff MG, Hayek SS, Pennathur S, Kretzler M, Pop-Busui R. Covid-19 and diabetes: A collision and collusion of two diseases. *Diabetes.* 2020;69:2549–65.
67. Abate, Checkol, Mantedafro, Basu. Prevalence and risk factors of mortality among hospitalized patients with COVID-19 : A systematic review and Meta-analysis. *Bull World Health Organ.* 2020;1–26.
68. Luo L, Fu M, Li Y, Hu S, Luo J, Chen Z, et al. The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis. *Clin Cardiol.* 2020;43(12):1478–93.
69. Cascella M, Rajnik M, Culemo A, Dulebohn S, Di Napoli F. Features, Evaluation, and Treatment of Coronavirus (COVID-19) [Internet]. *StatPearls* [Internet]. 2021. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK554776/>
70. Panduan Praktik Klinis COVID-19 RSUP Dr. M Djamil Padang. 2021;
71. Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, Pearson CAB, et al. COVID-19 length of hospital stay: A systematic review and data synthesis. *BMC Med.* 2020;18(270):1–22.
72. Neumann FJ, Sechtem U, Banning AP, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J.* 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425.
73. Maggioni AP. Review of the new ESC guidelines for the pharmacological management of chronic heart failure. *Eur Hear Journal, Suppl.* 2005;7(J):15-20. doi:10.1093/eurheartj/sui058.
74. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension.* 2020;75(6):1334-1357. doi:10.1161/HYPERTENSIONAHA.120.15026.

75. Krahn K. Hypertensive Urgency (Asymptomatic Severe Hypertension): Considerations for Management. [Internet]. 2016. Tersedia pada: <https://www.RxFiles.co/>
76. Inada M. Diabetes Mellitus and Glycosylated Hemoglobins. *Japanese J Clin Chem*. 1981;10(1):9-16. doi:10.14921/jsccl1971b.10.1\_9.
77. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor 364/MENKES/SK/V/2009.
78. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2020. Tersedia pada <http://www.ginasthma.org/>.
79. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for The Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2021. Tersedia pada <http://www.goldcopd.org/>
80. Hiß M, Kielstein JT. Chronic kidney disease (ckd). *Urol a Glance*. Published online 2014;145-150. doi:10.1007/978-3-642-54859-8\_30.
81. Kuriakose D, Xiao Z. Pathophysiology and treatment of stroke: Present status and future perspectives. *Int J Mol Sci*. 2020;21(20):1-24. doi:10.3390/ijms21207609.
82. Sharma A NS. Chronic Liver Disease. [Updated 2020 Feb 28]. In: StatPearls [Internet]. StatPearls Publishing; 2020. Accessed April 25, 2021. <https://www.ncbi.nlm.nih.gov/books/NBK554597/>.
83. About HIV/AIDS | HIV Basics | HIV/AIDS | CDC. Accessed April 25, 2021. <https://www.cdc.gov/hiv/basics/whatishiv.html>.
84. Purnell JQ. Definitions, Classification, and Epidemiology of Obesity. MDText.com, Inc.; 2000. Accessed April 25, 2021. <http://www.ncbi.nlm.nih.gov/pubmed/25905390>.
85. Sinha T. Tumors: Benign and Malignant. *Cancer Ther Oncol Int J*. 2018;10(3):1-3. doi:10.19080/ctoj.2018.10.555790.
86. Verma AA, Hora T, Jung HY, Fralick M, Malecki SI, Lapointe-Shaw L, et al. Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area. *CMAJ*. 2021: 1-9.
87. Siordia JA. Epidemiology and clinical features of COVID-19: a review of current literature. *Journal of Clinical Virology*. 2020; 127: 1-7.
88. Giannouchos TV, Sussman RA, Mier JM, Poulas K, Farsalinos K. Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases. *European Respiratory journal*. 2020: 1-30.
89. Wen S, Prasad A, Freeland K, Podury S, Patel J, Subedi R, et al. Clinical characteristics and outcomes of COVID-19 in West Virginia. *Viruses*. 2021; 13(835): 1-14.
90. Abhilasha, Mitra P, Suri S, Goyal T, Misra R, Singh K, et al. Association of comorbidities with coronavirus disease 2019: a review. *Ann Natl Acad Med Sci*. 2020: 1-9.

91. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis. *International Journal of Infectious Diseases*. 2020; 99: 47-56.
92. Fresan U, Guevara M, Trobajo-Sanmartin C, Burgui C, Ezpeleta C, Castilla J. Hypertension and related comorbidities as potential risk factors for COVID-19 hospitalization and severity: a prospective population-based cohort study. *Journal of Clinical Medicine*. 2021; 10(1194): 1-11.
93. Phelps M, Christensen DM, Gerds T, Fosbol E, Torp-Pedersen C, Schou M, et al. Cardiovascular comorbidities as predictors for severe COVID-19 infection or death. *European Heart Journal*. 2021; 7: 172-180.
94. Wei Z, Qiao R, Chen J, Huang J, Wu H, Wang W, et al. The influence of pre-existing hypertension on coronavirus disease 2019 patients. *Epidemiology and Infection*. 2021; 149: 1-7.
95. Wang X, Zhang H, Du H, Ma R, Nan Y, Zhang T. Risk factors for COVID-19 in patients with hypertension. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2021: 1-9.
96. Zaenab A, Jose V, Cynthia C, Yousuf Z, Claudia M, Hamed S. The effects of comorbidities on COVID-19 patients admitted to the hospital. *Fam Med Med Sci Res*. 2021; 10(2): 1-7.
97. Alshaikh MK, Alotair H, Alnajjar F, Sharaf H, Alhafi B, Alashgar L, Aljuaid M. Cardiovascular risk factors among patients infected with COVID-19 in Saudi Arabia. *Vascular Health and Risk Management*. 2021; 17: 161-168.
98. Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, Wright O, et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. *PLoS ONE*. 2021; 16(3): 1-12.
99. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis. *Intervirolgy*. 2021; 64: 36-47.
100. Jang SY, Seon J, Yoon S, Park S, Lee SH, Oh I. Comorbidities and factors determining medical expenses and length of stay for admitted COVID-19 patients in Korea. *Risk Management and Healthcare Policy*. 2021; 14: 2021-2033.
101. Alwafi H, Naser AY, Qanash S, Brinji AS, Ghazzawi MA, Alotaibi B, et al. Predictors of length of hospital stay, mortality, and outcomes among hospitalised COVID-19 patients in Saudi Arabia: a cross-sectional study. *Journal of Multidisciplinary Healthcare*. 2021; 14: 839-852.
102. Bae S, Kim SR, Kim M, Shim WJ, Park S. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. *Heart*. 2021; 107: 373-380.
103. Yi Y, Xu Y, Jiang H, Wang J. Cardiovascular disease and COVID-19: insight from

- cases with heart failure. *Front Cardiovasc Med.* 2021; 8: 1-6.
104. Ishigami J, Kou M, Ding N, Matsushita K. Cardiovascular disease and coronavirus disease 2019: epidemiology, management, and prevention. *Current Epidemiology Reports.* 2021; 8: 1-8.
  105. Hann Ng W, Tipih T, Makoah NA, Vermeulen J, Goedhals D, Sempa JB, et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. *mbio.* 2021; 12(1): 1-12.
  106. Corrao S, Pinelli K, Vacca M, Raspanti M, Argano C. Type 2 diabetes mellitus and COVID-19: a narrative review. *Front Endocrinol.* 2021; 12: 1-10.
  107. Silverio A, Maio MD, Citro R, Esposito L, Iuliano G, Bellino M, et al. Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients. *BMC Cardiovasc Disord.* 2021; 21(23): 1-13.

